Cargo Therapeutics will use most of the IPO proceeds for clinical testing of a cell therapy engineered to overcome a common way cancers develop resistance. This program is based on research from the National Cancer Institute.
Cargo Therapeutics is developing CAR T-cell therapies that overcome ways cancers evade currently available treatments. True to its name, the startup’s approach involves putting more cargo and more complex cargo onto engineered T cells.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bind to targets previously deemed undruggable.
Sierra Oncology myelofibrosis drug momelotinib achieved the main and secondary goals of a pivotal test and the biotech now plans to seek FDA approval. Sierra acquired momelotinib from Gilead Sciences after that company stopped work on the drug due to mixed results in Phase 3 testing.
Evidation, launched as a research app where people can opt into virtual clinical trials, now plans to offer digital health programs. The company recently raised $153 million in new funding.
Human API, a startup making it easier for consumers to share their health data, raised $20 million in funding. The company plans to use the funds to build out new features for clinical trial recruitment, insurance and digital health
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
MedCity spoke with Evidation and BrightInsight, two startups that have recently announced funding rounds, amid a Covid-19 pandemic worsening in the U.S.
The Rochester, Minnesota-based healthcare system and San Mateo, California-based population genomics company plan to launch the study in the next few weeks.
The company, led by a Gilead Sciences veteran, plans to use the platform to find drugs that go after "undruggable" targets.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Patients using the offering from the startup, MORE Health, can get access to physicians and services at Boston Children's Hospital and Nationwide Children's Hospital.
At a workshop convening digital therapeutics companies at the DTX West meeting in San Mateo, California, stakeholders debated what was necessary to build successful business models in the industry while navigating a nascent regulatory pathway.
The company, whose technology pairs with the Apple Watch and detects hand gestures, has a new feature that includes a reminder for mealtime insulin administration.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
Tuition.io, a startup based in Santa Monica, California, enables companies to offer a benefit that can help workers manage and repay their student loans.